Ergothioneine: The 'Longevity Vitamin' from Mushrooms and Its Cellular Antioxidant Role

Ergothioneine is an unusual sulphur-containing amino acid that humans cannot synthesise. We rely entirely on dietary intake — primarily from mushrooms — and our bodies actively transport it into tissues using a dedicated transporter (SLC22A4, also called OCTN1). Cells that are most exposed to oxidative stress — red blood cells, lens of the eye, bone marrow, liver, kidneys — accumulate the highest concentrations. Researchers like Bruce Ames have argued ergothioneine deserves classification as a "longevity vitamin": not essential to prevent acute deficiency, but plausibly important for healthy ageing.

What new human data suggests

A 2020 Singapore cohort study found that lower plasma ergothioneine levels predicted higher risk of cognitive decline and frailty over a five-year follow-up [1]. Independent NHANES analyses in older U.S. adults linked higher serum ergothioneine to lower all-cause mortality [2]. These are observational, so causation is uncertain — people who eat mushrooms may live healthier lifestyles overall — but the dedicated cellular transporter is biologically suggestive that the body treats this molecule as worth conserving.

Mechanism: more than a generic antioxidant

In test-tube assays ergothioneine quenches singlet oxygen, hydroxyl radicals, and hypochlorous acid efficiently. Unlike glutathione, it resists auto-oxidation and accumulates in mitochondria, where it appears to protect against ferroptosis (iron-dependent cell death) [3]. Animal studies show neuroprotective effects in models of Parkinson's and ischaemic injury, with rodent dosing in the 5–70 mg/kg range [4].

Dietary intake vs supplementation

Mushrooms are the only meaningful dietary source. Oyster, king trumpet, and porcini contain particularly high amounts (3–5 mg per 100 g cooked), while white button mushrooms supply roughly 0.4 mg per 100 g. A daily serving of 100 g of mushrooms provides 1–5 mg, enough to maintain plasma levels in most adults [5]. Purified supplements (5–25 mg capsules) raise blood concentrations measurably, but no clinical trial has yet demonstrated a meaningful health outcome from supplementation alone [6].

Safety and current limitations

EFSA reviewed synthetic ergothioneine in 2017 and considered it safe up to 30 mg/day for adults [7]. Adverse events in human trials have been minimal, but trials have been short (≤12 weeks) and small (typically <50 participants). The honest position is: ergothioneine is biologically interesting, dietary sources are cheap and palatable, and supplementation is plausibly safe but unproven for any specific endpoint.

Practical takeaway

Eating cooked mushrooms several times a week is the lowest-risk way to raise ergothioneine status and brings other benefits (fibre, vitamin D in UV-treated mushrooms, beta-glucans). A purified supplement is a reasonable experiment for someone who dislikes mushrooms, but should not be marketed as anti-ageing — the trial evidence is not yet there.

How ergothioneine fits into the broader antioxidant network

Cells deploy a layered antioxidant defence: glutathione handles the bulk of cytosolic redox balance, vitamin E protects membrane lipids, and superoxide dismutase scavenges superoxide radicals. Ergothioneine occupies a more specialised niche — it concentrates in mitochondria and lysosomes, two compartments where iron-driven oxidative damage is concentrated and where glutathione access is limited. Its resistance to auto-oxidation means it persists in the cell long enough to act, unlike vitamin C which is consumed rapidly. This complementary positioning is part of why several research groups argue ergothioneine should be considered alongside the established antioxidant vitamins rather than as a curiosity.

What still needs to be answered

Three open questions matter for anyone deciding whether to supplement. First, is the inverse association between blood ergothioneine and mortality causal or a marker of generally healthy diet patterns? Mendelian randomisation studies using genetic variants in the OCTN1 transporter would help. Second, do supplements actually replicate the tissue distribution achieved by dietary intake from mushrooms? Pharmacokinetic studies have measured plasma but not the tissue-specific concentrations that may matter most. Third, do at-risk populations — older adults with cognitive complaints, people with metabolic syndrome — experience clinical benefit from supplementation, or only biomarker changes? Trials addressing these are being launched but results will take years.